PCI: safety and efficacy of ticagrelor monotherapy after 1 month dual antiplatelet therapy

  • Franzone A & al.
  • J Am Coll Cardiol
  • 5 Nov 2019

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • In patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stent, ticagrelor monotherapy after 1 month dual antiplatelet therapy (DAPT) was non-inferior to conventional therapy in preventing all-cause mortality, non-fatal myocardial infarction (MI), non-fatal stroke or urgent target vessel revascularisation (TVR) at 2 years.
  • Ticagrelor therapy did not decrease the risk for major bleeding compared with conventional treatment.

Why this matters

  • The GLOBAL LEADERS study demonstrated that DAPT with 90-mg ticagrelor twice daily plus 1 month aspirin followed by 23 month ticagrelor did not reduce the composite of all-cause death or MI compared with 1 year DAPT followed by aspirin alone.
  • Future studies should focus on mechanisms responsible for better late outcomes in those who stop aspirin and continue ticagrelor monotherapy 1 month after PCI.

Study design

  • Study included 7585 patients who underwent PCI from the 20 top-enrolling sites of the GLOBAL LEADERS study.
  • Of 7585 patients, 3794 were allocated to the intervention group (1-month DAPT followed by 23 months ticagrelor) and 3791 to conventional group (1-year DAPT followed by aspirin alone).
  • Coprimary outcomes were divided into:
    • efficacy outcomes: composite of death, MI, stroke and urgent TVR and
    • safety outcomes: Bleeding Academic Research Consortium (BARC) 3 or 5 bleeding events.
  • Funding: None disclosed.

Key results

  • At 2 years, intervention therapy was non-inferior to convention therapy in reducing the rate of a composite of death, MI, stroke and urgent TVR (rate ratio [RR], 0.85; 95% CI, 0.72-0.99; Pnon-inferiority<.001>
  • Intervention vs conventional group did not differ in rates of BARC 3 or 5 bleeding (RR, 1.00; 95% CI, 0.75-1.33; P=.986).
  • After 1 year post-PCI, intervention vs conventional group had reduction in the risk for:
    • MI (RR, 0.54; 95% CI, 0.33-0.88; Pinteraction=.062),
    • composite of CV death or MI (RR, 0.69; 95% CI, 0.48-0.98; Pinteraction=.196) and
    • definite stent thrombosis (RR, 0.14; 95% CI, 0.03-0.63; Pinteraction=.007).

Limitations

  • Study included consecutive patients from the highest enrolling sites, rather than randomly selected patients from all sites.
  • Adherence to allocated treatment was lower in the intervention group.